Development of a safe anticancer drug by using oligosaccharide multiplicity

2015 Fiscal Year Final Research Report

• Project/Area Number: 26640106
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Juntendo University
• Principal Investigator: Hosomi Osamu 順天堂大学, スポーツ健康科学部, 客員教授 (30134274)
• Co-Investigator(Kenkyū-buntansha): SASAKI Hiraku 順天堂大学, スポーツ健康科学部, 准教授 (20384969)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: オリゴ糖 / 多様性 / がん細胞 / 抗がん剤 / アポトーシス / グルコサミン / 副作用

Outline of Final Research Achievements

We have developed oligosaccharide (Galα1-6GlcNH2) which suppresses proliferation of a human leukemia cell hard and have advanced a study for the effect of the oligosaccharide by using mice. If MelNH2 is a safe anticancer drug for body and has scarcely any side effect like a usual anticancer drug, we expect it can contribute widely to society.
Elucidation of the mechanism which a cancer cell takes MelNH2 in is left. However we find that MelNH2 causes chromatin aggregation of a cancer cell, and that release and cohesion of a calcium ion from ER. Thus we expect that these affects of MelNH2 to cancer cell induces apoptosis.We observed over expressions of metallothionein genes of K562 cell by a DNA microarray and RT-PCR, indicating that MelNH2 cytotoxicity against cancer cell exceeds the limit to which a cancer cell can correspond. Moreover, the binding reaction of hnRNP-A1 and MelNH2 was identified, indicating that a splicing activity of hnRNP-A1 is inhibited by MelNH2.

Free Research Field

糖鎖科学